[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)
date : 11/5/2020
Tags: AMR
AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) held a Roundtable on Medical Fee System Measures to Discourage the Spread of AMR.
This meeting was held on the basis of AMR Alliance Japan’s overarching policy recommendations published in July 2019 which called for the promotion of measures through the medical fee system to incentivize behaviors that could help to discourage the spread of antimicrobial resistance (AMR).
AMR Alliance Japan members discussed recommendations toward the 2022 revision of the medical fee system. Based on the discussion, AMR Alliance Japan decided on the key items to be targeted in future proposals on the medical fee system revision.
In light of the situation with novel coronavirus, this meeting was carried out primarily online.
■Overview
Date and time: Wednesday, September 28, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
Roundtable Discussion
・Key items for AMR Alliance Japan’s Medical Fee System Revision Proposal
・Future Plans
■Roundtable Speakers (alphabetical order by last name):
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Masashi Kawata (Senior Manager, Public Affairs & Policy, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Yuri Miura (Senior Industry Policy Specialist, Public and Industrial Policy, Health Policy, MSD K.K.)
Masaaki Miyakawa (Executive Board Member, Japan Medical Association)
Choichiro Miyazaki (Vice Chairman, Japan Pharmaceutical Association)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Toshiyuki Sakaeda (President, The Japanese Society of Therapeutic Drug Monitoring / Professor, Department of Pharmacokinetics, Kyoto Pharmaceutical University)
Makoto Seno (Marketing Director, Nippon Becton Dickinson Company Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
■Moderator:
Yuki Awano (AMR Alliance Japan Secretariat / Associate, HGPI)
Top Research & Recommendations Posts
- [Policy Recommendations] Joint Statement “Protecting the Health of Both the Planet and People — A Japan-Model Planetary Health Strategy to Turn the Climate Crisis into an Opportunity for Health, the Economy, and Growth” (June 24, 2026)
- [Policy Recommendations] Toward Further Advancement of Measures Against Antimicrobial Resistance (AMR) (July 15, 2026)
- [Announcement] HGPI Joins the UHC2030 Task Force for the 2027 UN High-Level Meeting on UHC (July 6, 2026)
- [Research Report] Energy Conservation and Greenhouse Gas Emissions Reduction in Healthcare Facilities: Case Studies from New Construction and Facility Renewal (March 16, 2026)
- [Research Report] AMR Policy Update #6: The New Global Action Plan on AMR (Part 1)
- [Research Report] AMR Policy Update #7: The New Global Action Plan on AMR (Part 2)
- [Policy Recommendations] Hearing Loss Project “Recommendations on Coherent Countermeasures for Hearing Loss Throughout the Life Course: Building a Society Where Everyone Can Access Appropriate Hearing Care” (July 30, 2026)
- [Research Report] AMR Policy Update #9: Stockholm Residents’ Awareness and Practices in Returning and Recycling Pharmaceuticals: Findings from Local Interviews (July 15, 2026)
- [Policy Recommendations] Expectations for a System that Spans Diseases, Ministries, and Agencies for the Effective Promotion of Patient and Public Involvement (PPI) in Research and Development (June 30, 2026)
- [Activity Report] HGPI Contributed to the Development of the Civil 7 (C7) Global Health Working Group’s Climate and Health Thematic Brief for the G7 (June 25, 2026)
Featured Posts
-
2026-06-19
[Recommendations] Strengthening Epidemiology Education in the Veterinary Field for the One Health Era (June 19, 2026)
-
2026-07-21
[Announcement] Announcement of the 2nd Kiyoshi Kurokawa Award Recipient
-
2026-07-22
[Registration Open] Second Session of the Planetary Health Academy (Starts September 2026)
-
2026-07-31
[Policy recommendation] Reliable Policy Implementation for Early Detection and Early Intervention of Chronic Kidney Disease (CKD) (July 31, 2026)
-
2026-08-05
[Registration Open] (Webinar) The 4th J-PEP Seminar “The History of PPI in Japan and My Own PPI Journey” (September 30, 2026)



